ROWLAND LLOYD A (General Counsel) sold 7.8% of their position (10.20K shares) of CYTOMX THERAPEUTICS, INC. on the open market
Open‑market sale worth $6.1K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/20/2025ACC: 0001610717-25-000083
Officer· General Counsel
Since Nov 2018
-10.20K
Net shares
Net seller
$6.1K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
10.20K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−10.20K
Price / share
$0.60
Trade value
$6.11K
% of position
7.8%
3/18/2025
130.80K→120.59K
Total
Net shares
−10.20K
Net value
-$6.11K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/18/2025 | S · Sale | −10.20K | $0.60 | $6.11K | 7.8% | 130.80K | 120.59K |
| Total | −10.20K | -$6.11K | ||||||
Derivative Transactions0
No derivative transactions reported